

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE  
WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

October 13, 2000

**(OVERNIGHT COURIER 10/13/00)**

Dockets Management Branch, HFA-305  
Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Citizen Petition**

The undersigned submits this petition in quadruplicate pursuant to 505 (j) (2) (B) of the Federal Food, Drug and Cosmetic Act and 21 CFR § 10.20 and 10.30 to request the Commissioner of the Food and Drug Administration to make a determination that an Abbreviated New Drug Application (ANDA) may be submitted for Ursodiol Oral Suspension, 20 mg/mL in a ready-to-use form for oral administration.

**A. Action Requested**

The petitioner requests that a Commissioner of the Food and Drug Administration make a determination that the drug product, Ursodiol Oral Suspension, 20 mg/mL, is suitable for evaluation under an ANDA. The reference product is Actigall® Ursodiol Oral Capsule, 300 mg (NDA 19-594). This Petition requests a change in dosage form from that of the approved capsule to a liquid form.

**B. Statement of Grounds**

The Federal Food, Drug and Cosmetic Act provides for the submission of an ANDA for a drug that differs in dosage form from a listed drug, provided the FDA has approved a petition that proposed filing of such an application. This petition involves a change in dosage form from that of the listed drug. The proposed drug product is equivalent in use, dosage and route of administration to the listed drug, Actigall® (Ursodiol Oral Capsule, 300 mg). This petition proposes to market an oral suspension as an alternative dosage form providing for greater compliance for patients who have difficulty swallowing, or cannot swallow capsules, and for ease of titration while seeking the effective dose level. Dosing of Ursodiol in treatment of radiolucent gallbladder stones is 8-10 mg/kg/day given in two or three divided doses. A suspension dosage form will allow for optimal dosage titration for each patient for dissolution of gallstones. A suspension

0879 00 OCT 16 PM 12

00P-1568

www.lachmanconsultants.com

LCS@lachmanconsultants.com

CPI

dosage will also allow practitioners to titrate to the lowest effective dose, which may decrease adverse reactions commonly experienced with the capsule dosage form.

The petitioner requests that the Agency grant a full waiver of the requirements of Paragraph (A) under 21 CFR § 201.23 "Required Pediatric Studies" because the proposed product does not represent a meaningful benefit over existing treatments, nor is it likely to be used in a substantial number of pediatric patients. Our reasoning is as follows:

Ursodiol is not listed in Docket No. 98N-0056, Update of List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population (May 19, 2000), Attachment A, Pediatric Priority List of Drugs Regulated by the Center for Drug Evaluation and Research. Therefore, the FDA has not designated Ursodiol as a drug product that is likely to produce health benefits in the pediatric population.

Most patients who have gallstones do not develop symptoms. Acute Cholecystitis occurs when a gallstone becomes lodged in the neck of the gallbladder. The most frequently used treatment for Acute Cholecystitis is Laparoscopic Cholecystectomy. Nonsurgical approaches are used only in special situations. Although Ursodeoxycholic Acid is primarily indicated in patients for whom surgery is not an option, other treatment alternatives (watchful waiting, Contact Dissolution Therapy, Extracorporeal Shockwave lithotripsy, Endoscopic Retrograde Cholangiography, Percutaneous Therapy) are available. Therefore, this product does not represent a meaningful benefit for pediatric patients over these existing treatments.

Populations at risk for developing gallstones are women, people over 60, Native Americans, Mexican-Americans, overweight men and women, people who fast or lose a lot of weight quickly, pregnant women, women on hormone therapy, and women who use birth control pills. In regard to the size of the pediatric population with symptomatic gallstones, little demographic information could be found in the literature. The presence of gallstones is not commonly associated with the pediatric population, although the condition does infrequently occur in this population. The lack of demographic information for the pediatric population suggests a negligible population size. Limit this apparently small population to "patients for whom elective Cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those

patients who refuse surgery" (as indicated in the approved labeling for Actigall), and it is expected that the population is quite limited. The petitioner's review of the literature suggests that it is likely that a population of less than 50,000 pediatric patients is affected. Therefore, the product is not likely to be used in a substantial number of patients.

Support for the above statements in regard to a request for a waiver of pediatric studies was obtained from:

Docket No. 98N-0056, Update of List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population (May 19, 2000), Attachment A, Pediatric Priority List of Drugs Regulated by the Center for Drug Evaluation and Research.

American College of Physicians. Guidelines for the Treatment of Gallstones. *Ann Intern Med* 1993; **119**: 620-622.

American Pharmaceutical Association, *Pediatric Dosage Handbook*, 5<sup>th</sup> Edition 1998; 1111-1112.

Childrens Hospital Los Angeles, *Pediatric Dosing Handbook and Formulary*, 12<sup>th</sup> Edition 1997; 772-773.

*The Merck Manual*, 17<sup>th</sup> Edition 1999; 399-406.

NIH, National Digestive Diseases Information Clearinghouse, [www.niddk.nih.gov](http://www.niddk.nih.gov)

Ransohoff DF, Gracie WA. Treatment of gallstones. *Ann Intern Med* 1993; **119**: 606-619.

Finally, the labeling for the proposed product is the same as the reference-listed drug, except for the change in strength and dosage form reflected in this petition. The draft labeling and approved labeling for the reference-listed drug are attached.

### C. Environmental Impact

An environmental assessment on the action requested in this petition qualifies for a categorical exclusion from the requirements of an environmental assessment or impact statement under 21 CFR 25.31(a).


**D. Economic Impact**

Pursuant to 21 CFR 10.30(b), economic impact information is to be submitted when requested by the Commissioner. Information will be promptly submitted, if requested.

**E. Certification**

Lachman Consultant Services, Inc. certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

Respectfully submitted,

A handwritten signature in cursive script that reads "Gordon R. Johnston". To the right of the signature is a circled monogram "BJ".

Gordon R. Johnston  
Associate

GJ/bh

Attachments: 1) *Draft Labeling*  
2) *Actigall Package Insert Labeling*

cc: G. Davis, OGD  
L. Lachman  
R. Pollock

Pkk0286

# **ATTACHMENT 1**

Citizen Petition  
Ursodiol for Oral Administration

Labeling for petitioner's product:  
Ursodiol Oral Suspension, 20 mg/mL

- <sup>1</sup> Reference Drug: states drug tradename, "Actigall"  
Petitioner: will use generic drug name "ursodiol" in place of tradename
- <sup>2</sup> Reference Drug: states outdated federal caution statement  
Petitioner: will replace federal caution statement with "Rx only"
- <sup>3</sup> Reference Drug: dosage form stated as "capsules"  
Petitioner: will change dosage form to "oral suspension"
- <sup>4</sup> Reference Drug: How Supplied section states information on capsule product  
Petitioner: How Supplied section states information on suspension product (storage conditions will be revised accordingly but have not yet been determined for the proposed suspension)
- <sup>5</sup> Reference Drug: states information about distributor Novartis  
Petitioner: will state information about manufacturer of the suspension

9. Keep the patch dry, if possible, to prevent it from falling off. Limited contact with water, however, as in bathing or swimming, will not affect the system. In the unlikely event that the patch falls off, throw it away and put a new one behind the other ear.

This leaflet presents a summary of information about Transderm Scop. If you would like more information or if you have any questions, ask your doctor or pharmacist. A more technical leaflet is available, written for your doctor. If you would like to read the leaflet, ask your pharmacist to show you a copy. You may need the help of your doctor or pharmacist to understand some of the information.

Distributed by:  
Novartis Consumer Health, Inc.  
Summit, N.J. 07901-1312

Shown in Product Identification Guide, page 324

## Novartis Pharmaceuticals Corporation

NOVARTIS PHARMACEUTICALS CORPORATION  
59 Route 10  
East Hanover, NJ 07936  
(for branded products)

GENEVA PHARMACEUTICALS, INC.  
A NOVARTIS COMPANY  
2655 West Midway Boulevard  
PO Box 446  
Broomfield, CO 80038-0446  
(for branded generic product listing refer to Geneva Pharmaceuticals, Inc.)

### For Information Contact (branded products):

Customer Response Department  
(888) NOW-NOVARTIS (888-669-6682)  
Global Internet Address:  
<http://www.novartis.com>

### For Information Contact (branded generic products):

Customer Support Department  
(800) 525-8747  
(303) 466-2400  
FAX: (303) 469-6467

### ACTIGALL®

ursodiol USP  
Capsules oral suspension<sup>3</sup>

**Caution:** Federal law prohibits dispensing without prescription. Rx only<sup>2</sup>

The following prescribing information is based on official labeling in effect on August 1, 1998.


### SPECIAL NOTE

Gallbladder stone dissolution with **Actigall** treatment requires months of therapy. Complete dissolution does not occur in all patients and recurrence of stones within 5 years has been observed in up to 50% of patients who do dissolve their stones on bile acid therapy. Patients should be carefully selected for therapy with ursodiol, and alternative therapies should be considered.

### DESCRIPTION

**Actigall** is a bile acid available as 300-mg capsules suitable for oral administration.

**Actigall** is ursodiol USP (ursodeoxycholic acid), a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the bile of certain species of bears. It is a bitter-tasting, white powder freely soluble in ethanol, methanol, and glacial acetic acid; sparingly soluble in chloroform; slightly soluble in ether; and insoluble in water. The chemical name for ursodiol is 3 $\alpha$ , 7 $\beta$ -dihydroxy-5 $\beta$ -cholan-24-oic acid (C<sub>24</sub>H<sub>40</sub>O<sub>4</sub>). Ursodiol USP has a molecular weight of 392.58. Its structure is shown below:



**Inactive Ingredients.** Colloidal silicon dioxide, ferric oxide, gelatin, magnesium stearate, starch (corn), and titanium dioxide.

### CLINICAL PHARMACOLOGY

About 90% of a therapeutic dose of **Actigall** is absorbed in the small bowel after oral administration. After absorption, ursodiol enters the portal vein and undergoes efficient extraction from portal blood by the liver (i.e., there is a large "first-pass" effect) where it is conjugated with either glycine or taurine and is then secreted into the hepatic bile ducts. Ursodiol in bile is concentrated in the gallbladder and expelled into the duodenum in gallbladder bile via the cystic and common ducts by gallbladder contractions provoked by physiologic responses to eating. Only small quantities of ursodiol appear in the systemic circulation and very small amounts are excreted into urine. The sites of the drug's therapeutic actions are in the liver, bile, and gut lumen.

Beyond conjugation, ursodiol is not altered or catabolized appreciably by the liver or intestinal mucosa. A small proportion of orally administered drug undergoes bacterial degradation with each cycle of enterohepatic circulation. Ursodiol can be both oxidized and reduced at the 7-carbon, yielding either 7-keto-lithocholic acid or lithocholic acid, respectively. Further, there is some bacterially catalyzed deconjugation of glyco- and tauro- ursodeoxycholic acid in the small bowel. Free ursodiol, 7-keto-lithocholic acid, and lithocholic acid are relatively insoluble in aqueous media and larger proportions of these compounds are lost from the distal gut into the feces. Reabsorbed free ursodiol is reconstituted by the liver. Eighty percent of lithocholic acid formed in the small bowel is excreted in the feces, but the 20% that is absorbed is sulfated at the 3-hydroxyl group in the liver to relatively insoluble lithocholyl conjugates which are excreted into bile and lost in feces. Absorbed 7-keto-lithocholic acid is stereospecifically reduced in the liver to chenodiol.

Lithocholic acid causes cholestatic liver injury and can cause death from liver failure in certain species unable to form sulfate conjugates. Lithocholic acid is formed by 7-dehydroxylation of the dihydroxy bile acids (ursodiol and chenodiol) in the gut lumen. The 7-dehydroxylation reaction appears to be alpha-specific, i.e., chenodiol is more efficiently 7-dehydroxylated than ursodiol and, for equimolar doses of ursodiol and chenodiol, levels of lithocholic acid appearing in bile are lower with the former. Man has the capacity to sulfate lithocholic acid. Although liver injury has not been associated with ursodiol therapy, a reduced capacity to sulfate may exist in some individuals, but such a deficiency has not yet been clearly demonstrated.

### Pharmacodynamics

Ursodiol suppresses hepatic synthesis and secretion of cholesterol, and also inhibits intestinal absorption of cholesterol. It appears to have little inhibitory effect on synthesis and secretion into bile of endogenous bile acids, and does not appear to affect secretion of phospholipids into bile. With repeated dosing, bile ursodeoxycholic acid concentrations reach a steady state in about 3 weeks. Although insoluble in aqueous media, cholesterol can be solubilized in at least two different ways in the presence of dihydroxy bile acids. In addition to solubilizing cholesterol in micelles, ursodiol acts by an apparently unique mechanism to cause dispersion of cholesterol as liquid crystals in aqueous media. Thus, even though administration of high doses (e.g., 15-18 mg/kg/day) does not result in a concentration of ursodiol higher than 60% of the total bile acid pool, ursodiol-rich bile effectively solubilizes cholesterol. The overall effect of ursodiol is to increase the concentration level at which saturation of cholesterol occurs.

The various actions of ursodiol combine to change the bile of patients with gallstones from cholesterol-precipitating to cholesterol-solubilizing, thus resulting in bile conducive to cholesterol stone dissolution.

After ursodiol dosing is stopped, the concentration of the bile acid in bile falls exponentially, declining to about 5%-10% of its steady-state level in about 1 week.

### Clinical Results

#### Gallstone Dissolution

On the basis of clinical trial results in a total of 868 patients with radiolucent gallstones treated in 8 studies (three in the U.S. involving 282 patients, one in the U.K. involving 130 patients, and four in Italy involving 456 patients) for periods ranging from 6-78 months with **Actigall** doses ranging from about 5 to 20 mg/kg/day, an **Actigall** dose of about 8-10 mg/kg/day appeared to be the best dose. With an **Actigall** dose of about 10 mg/kg/day, complete stone dissolution can be anticipated in about 30% of unselected patients with uncalcified gallstones <20 mm in maximal diameter treated for up to 2 years. Patients with calcified gallstones prior to treatment, or patients who develop stone calcification or gallbladder nonvisualization on treatment, and patients with stones >20 mm in maximal diameter rarely dissolve their stones. The chance of gallstone dissolution is increased up to 50% in patients with floating or floatable stones (i.e., those with high cholesterol content), and is

inversely related to stone size for those <20 mm in maximal diameter. Complete dissolution was observed in 81% of patients with stones up to 5 mm in diameter. Age, sex, weight, degree of obesity, and serum cholesterol level are not related to the chance of stone dissolution with **Actigall**. A nonvisualizing gallbladder by oral cholecystogram prior to the initiation of therapy is not a contraindication to **Actigall** therapy (the group of patients with nonvisualizing gallbladders in the **Actigall** studies had complete stone dissolution rates similar to the group of patients with visualizing gallbladders). However, gallbladder nonvisualization developing during ursodiol treatment predicts failure of complete stone dissolution and in such cases therapy should be discontinued.

Partial stone dissolution occurring within 6 months of beginning therapy with **Actigall** appears to be associated with a >70% chance of eventual complete stone dissolution with further treatment; partial dissolution observed within 1 year of starting therapy indicates a 40% probability of complete dissolution.

Stone recurrence after dissolution with **Actigall** therapy was seen within 2 years in 8/27 (30%) of patients in the U.K. studies. Of 16 patients in the U.K. study whose stones had previously dissolved on chenodiol but later recurred, 11 had complete dissolution on **Actigall**. Stone recurrence has been observed in up to 50% of patients within 5 years of complete stone dissolution on ursodiol therapy. Serial ultrasonographic examinations should be obtained to monitor for recurrence of stones, bearing in mind that radiolucency of the stones should be established before another course of **Actigall** is instituted. A prophylactic dose of **Actigall** has not been established.

### Gallstone Prevention

Two placebo-controlled, multicenter, double-blind, randomized, parallel group trials in a total of 1316 obese patients were undertaken to evaluate **Actigall** in the prevention of gallstone formation in obese patients undergoing rapid weight loss. The first trial consisted of 1004 obese patients with a body mass index (BMI)  $\geq 38$  who underwent weight loss induced by means of a very low calorie diet for a period of 16 weeks. An intent-to-treat analysis of this trial showed that gallstone formation occurred in 23% of the placebo group, while those patients on 300, 600, or 1200 mg/day of **Actigall** experienced a 6%, 3%, and 2% incidence of gallstone formation, respectively. The mean weight loss for this 16-week trial was 47 lb for the placebo group, and 47, 48, and 50 lb for the 300, 600, and 1200 mg/day **Actigall** groups, respectively.

The second trial consisted of 312 obese patients (BMI  $\geq 40$ ) who underwent rapid weight loss through gastric bypass surgery. The trial drug treatment period was for 6 months following this surgery. Results of this trial showed that gallstone formation occurred in 23% of the placebo group, while those patients on 300, 600, or 1200 mg/day of **Actigall** experienced a 9%, 1%, and 5% incidence of gallstone formation, respectively. The mean weight loss for this 6-month trial was 64 lb for the placebo group, and 67, 74, and 72 lb for the 300, 600, and 1200 mg/day **Actigall** groups, respectively.

### ALTERNATIVE THERAPIES

#### Watchful Waiting

Watchful waiting has the advantage that no therapy may ever be required. For patients with silent or minimally symptomatic stones, the rate of development of moderate-to-severe symptoms or gallstone complications is estimated to be between 2% and 6% per year, leading to a cumulative rate of 7% to 27% in 5 years. Presumably the rate is higher for patients already having symptoms.

#### Cholecystectomy

For patients with symptomatic gallstones, surgery offers the advantage of immediate and permanent stone removal, but carries a high risk in some patients. About 5% of cholecystectomized patients have residual symptoms or retained common duct stones. The spectrum of surgical risk varies as a function of age and the presence of disease other than cholelithiasis.

#### Mortality Rates for Cholecystectomy in the U.S.

(National Halothane Study, JAMA 1966; 197:775-8)  
27,600 Cholecystectomies (Smoothed Rates)  
Deaths/1000 Operations\*\*\*

| Low Risk Patients*   | Age (Yrs) | Cholecystectomy + Common Duct Exploration |       |
|----------------------|-----------|---|-------|
|                      |           | Cholecystectomy                           |       |
| Women                | 0-49      | .54                                       | 2.13  |
|                      | 50-69     | 2.80                                      | 10.10 |
| Men                  | 0-49      | 1.04                                      | 4.12  |
|                      | 50-69     | 5.41                                      | 19.23 |
| High Risk Patients** |           |   |       |
| Women                | 0-49      | 12.66                                     | 47.62 |
|                      | 50-69     | 17.24                                     | 58.82 |

Continued on next page

**Actigall—Cont.**

|     |       |       |        |
|-----|-------|-------|--------|
| Men | 0-49  | 24.39 | 90.91  |
|     | 50-69 | 33.33 | 111.11 |

\* In good health or with moderate systemic disease.

\*\* With severe or extreme systemic disease.

\*\*\* Includes both elective and emergency surgery.

Women in good health or who have only moderate systemic disease and are under 49 years of age have the lowest surgical mortality rate (0.054); men in all categories have a surgical mortality rate twice that of women. Common duct exploration quadruples the rates in all categories. The rates rise with each decade of life and increase tenfold or more in all categories with severe or extreme systemic disease.

**INDICATIONS AND USAGE**

1. Actigall is indicated for patients with radiolucent, noncalcified gallbladder stones <20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of Actigall beyond 24 months is not established.

2. Actigall is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

**CONTRAINDICATIONS**

1. Actigall will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. Hence, patients with such stones are not candidates for Actigall therapy.

2. Patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for Actigall therapy.

3. Allergy to bile acids.

**PRECAUTIONS****Liver Tests**

Ursodiol therapy has not been associated with liver damage. Lithocholic acid, a naturally occurring bile acid, is known to be a liver-toxic metabolite. This bile acid is formed in the gut from ursodiol less efficiently and in smaller amounts than that seen from chenodiol. Lithocholic acid is detoxified in the liver by sulfation and, although man appears to be an efficient sulfator, it is possible that some patients may have a congenital or acquired deficiency in sulfation, thereby predisposing them to lithocholate-induced liver damage.

Abnormalities in liver enzymes have not been associated with Actigall therapy and, in fact, Actigall has been shown to decrease liver enzyme levels in liver disease. However, patients given Actigall should have SGOT (AST) and SGPT (ALT) measured at the initiation of therapy and thereafter as indicated by the particular clinical circumstances.

**Drug Interactions**

Bile acid sequestering agents such as cholestyramine and colestipol may interfere with the action of Actigall by reducing its absorption. Aluminum-based antacids have been shown to adsorb bile acids in vitro and may be expected to interfere with Actigall in the same manner as the bile acid sequestering agents. Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion, and encourage cholesterol gallstone formation and hence may counteract the effectiveness of Actigall.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Ursodeoxycholic acid was tested in 2-year oral carcinogenicity studies in CD-1 mice and Sprague-Dawley rats at daily doses of 50, 250, and 1000 mg/kg/day. It was not tumorigenic in mice. In the rat study, it produced statistically significant dose-related increased incidences of pheochromocytomas of adrenal medulla in males ( $p=0.014$ , Peto trend test) and females ( $p=0.004$ , Peto trend test). A 78-week rat study employing intrarectal instillation of lithocholic acid and tauro-deoxycholic acid, metabolites of ursodiol and chenodiol, has been conducted. These bile acids alone did not produce any tumors. A tumor-promoting effect of both metabolites was observed when they were co-administered with a carcinogenic agent. Results of epidemiologic studies suggest that bile acids might be involved in the pathogenesis of human colon cancer in patients who had undergone a cholecystectomy, but direct evidence is lacking. Ursodiol is not mutagenic in the Ames test. Dietary administration of lithocholic acid to chickens is reported to cause hepatic adenomatous hyperplasia.

**Pregnancy Category B**

Reproduction studies have been performed in rats and rabbits with ursodiol doses up to 200-fold the therapeutic dose and have revealed no evidence of impaired fertility or harm to the fetus at doses of 20- to 100-fold the human dose in rats and at 5-fold the human dose (highest dose tested) in

rabbits. Studies employing 100- to 200-fold the human dose in rats have shown some reduction in fertility rate and litter size. There have been no adequate and well-controlled studies of the use of ursodiol in pregnant women, but inadvertent exposure of 4 women to therapeutic doses of the drug in the first trimester of pregnancy during the Actigall trials led to no evidence of effects on the fetus or newborn baby. Although it seems unlikely, the possibility that ursodiol can cause fetal harm cannot be ruled out; hence, the drug is not recommended for use during pregnancy.

**Nursing Mothers**

It is not known whether ursodiol is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Actigall is administered to a nursing mother.

**Pediatric Use**

The safety and effectiveness of Actigall in pediatric patients have not been established.

**ADVERSE REACTIONS**

The nature and frequency of adverse experiences were similar across all groups.

The following tables provide comprehensive listings of the adverse experiences reported that occurred with a 5% incidence level:

**GALLSTONE DISSOLUTION**

|                                   | Ursodiol<br>8-10 mg/kg/day<br>(N=155) |        | Placebo<br>(N=159) |        |
|-----------------------------------|---------------------------------------|--------|--------------------|--------|
|                                   | N                                     | (%)    | N                  | (%)    |
| <b>Body as a Whole</b>            |                                       |        |                    |        |
| Allergy                           | 8                                     | (5.2)  | 7                  | (4.4)  |
| Chest Pain                        | 5                                     | (3.2)  | 10                 | (6.3)  |
| Fatigue                           | 7                                     | (4.5)  | 8                  | (5.0)  |
| Infection Viral                   | 30                                    | (19.4) | 41                 | (25.8) |
| <b>Digestive System</b>           |                                       |        |                    |        |
| Abdominal Pain                    | 67                                    | (43.2) | 70                 | (44.0) |
| Cholecystitis                     | 8                                     | (5.2)  | 7                  | (4.4)  |
| Constipation                      | 15                                    | (9.7)  | 14                 | (8.8)  |
| Diarrhea                          | 42                                    | (27.1) | 34                 | (21.4) |
| Dyspepsia                         | 26                                    | (16.8) | 18                 | (11.3) |
| Flatulence                        | 12                                    | (7.7)  | 12                 | (7.5)  |
| Gastrointestinal Disorder         | 6                                     | (3.9)  | 8                  | (5.0)  |
| Nausea                            | 22                                    | (14.2) | 27                 | (17.0) |
| Vomiting                          | 15                                    | (9.7)  | 11                 | (6.9)  |
| <b>Musculoskeletal System</b>     |                                       |        |                    |        |
| Arthralgia                        | 12                                    | (7.7)  | 24                 | (15.1) |
| Arthritis                         | 9                                     | (5.8)  | 4                  | (2.5)  |
| Back Pain                         | 11                                    | (7.1)  | 18                 | (11.3) |
| Myalgia                           | 9                                     | (5.8)  | 9                  | (5.7)  |
| <b>Nervous System</b>             |                                       |        |                    |        |
| Headache                          | 28                                    | (18.1) | 34                 | (21.4) |
| Insomnia                          | 3                                     | (1.9)  | 8                  | (5.0)  |
| <b>Respiratory System</b>         |                                       |        |                    |        |
| Bronchitis                        | 10                                    | (6.5)  | 6                  | (3.8)  |
| Coughing                          | 11                                    | (7.1)  | 7                  | (4.4)  |
| Pharyngitis                       | 13                                    | (8.4)  | 5                  | (3.1)  |
| Rhinitis                          | 8                                     | (5.2)  | 11                 | (6.9)  |
| Sinusitis                         | 17                                    | (11.0) | 18                 | (11.3) |
| Upper Respiratory Tract Infection | 24                                    | (15.5) | 21                 | (13.2) |
| <b>Urogenital System</b>          |                                       |        |                    |        |
| Urinary Tract Infection           | 10                                    | (6.5)  | 7                  | (4.4)  |

**GALLSTONE PREVENTION**

|                               | Actigall<br>600 mg<br>(N=322) |        | Placebo<br>(N=325) |        |
|-------------------------------|-------------------------------|--------|--------------------|--------|
|                               | N                             | (%)    | N                  | (%)    |
| <b>Body as a Whole</b>        |                               |        |                    |        |
| Fatigue                       | 25                            | (7.8)  | 33                 | (10.2) |
| Infection Viral               | 29                            | (9.0)  | 29                 | (8.9)  |
| Influenza-like Symptoms       | 21                            | (6.5)  | 19                 | (5.8)  |
| <b>Digestive System</b>       |                               |        |                    |        |
| Abdominal Pain                | 20                            | (6.2)  | 39                 | (12.0) |
| Constipation                  | 85                            | (26.4) | 72                 | (22.2) |
| Diarrhea                      | 81                            | (25.2) | 68                 | (20.9) |
| Flatulence                    | 15                            | (4.7)  | 24                 | (7.4)  |
| Nausea                        | 56                            | (17.4) | 43                 | (13.2) |
| Vomiting                      | 44                            | (13.7) | 44                 | (13.5) |
| <b>Musculoskeletal System</b> |                               |        |                    |        |
| Back Pain                     | 38                            | (11.8) | 21                 | (6.5)  |
| Musculoskeletal Pain          | 19                            | (5.9)  | 15                 | (4.6)  |
| <b>Nervous System</b>         |                               |        |                    |        |
| Dizziness                     | 53                            | (16.5) | 42                 | (12.9) |
| Headache                      | 80                            | (24.8) | 78                 | (24.0) |

**Respiratory System**

|                                   |    |        |    |        |
|-----------------------------------|----|--------|----|--------|
| Pharyngitis                       | 10 | (3.1)  | 19 | (5.8)  |
| Sinusitis                         | 17 | (5.3)  | 18 | (5.5)  |
| Upper Respiratory Tract Infection | 40 | (12.4) | 35 | (10.8) |

**Skin and Appendages**

|          |    |       |   |       |
|----------|----|-------|---|-------|
| Alopecia | 17 | (5.3) | 8 | (2.5) |
|----------|----|-------|---|-------|

**Urogenital System**

|              |    |       |    |       |
|--------------|----|-------|----|-------|
| Dysmenorrhea | 18 | (5.6) | 19 | (5.8) |
|--------------|----|-------|----|-------|

**OVERDOSAGE**

Neither accidental nor intentional overdosing with Actigall has been reported. Doses of Actigall in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD<sub>50</sub> for ursodiol in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdoses with Actigall would probably be diarrhea, which should be treated symptomatically.

**DOSAGE AND ADMINISTRATION****Gallstone Dissolution**

The recommended dose for Actigall treatment of radiolucent gallbladder stones is 8-10 mg/kg/day given in 2 or 3 divided doses.

Ultrasound images of the gallbladder should be obtained at 6-month intervals for the first year of Actigall therapy to monitor gallstone response. If gallstones appear to have dissolved, Actigall therapy should be continued and dissolution confirmed on a repeat ultrasound examination within 1 to 3 months. Most patients who eventually achieve complete stone dissolution will show partial or complete dissolution at the first on-treatment reevaluation. If partial stone dissolution is not seen by 12 months of Actigall therapy, the likelihood of success is greatly reduced.

**Gallstone Prevention**

The recommended dosage of Actigall for gallstone prevention in patients undergoing rapid weight loss is 600 mg/day (300 mg b.i.d.).

**HOW SUPPLIED**

Capsules 300 mg—opaque, white, pink (imprinted Actigall 300 mg)

Bottles of 100 ..... NDC 0078-0219-05

Do not store above 30°C (86°F).

Dispense in light container (USP).

©97-12 (Rev. 12/97)

Distributed by 5  
Novartis Pharmaceuticals Corporation  
East Hanover, New Jersey 07936

Shown in Product Identification Guide, page 324

**ANAFRANIL®**

[aka frānil]

clomipramine hydrochloride  
Capsules


Caution: Federal law prohibits dispensing without prescription.

The following prescribing information is based on official labeling in effect on August 1, 1998.

**DESCRIPTION**

Anafranil, clomipramine hydrochloride, is an antiobsessional drug that belongs to the class (dibenzazepine) of pharmacologic agents known as tricyclic antidepressants. Anafranil is available as capsules of 25, 50, and 75 mg for oral administration.

Clomipramine hydrochloride is 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride and its structural formula is



Clomipramine hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, in methanol, and in methylene chloride, and insoluble in ethyl ether and in hexane. Its molecular weight is 351.3.

**Inactive Ingredients.** D&C Red No. 33 (25-mg capsules only), D&C Yellow No. 10, FD&C Blue No. 1 (60-mg capsules only), FD&C Yellow No. 6, gelatin, magnesium stearate, methylparaben, propylparaben, silicon dioxide, sodium lauryl sulfate, starch, and titanium dioxide.

**CLINICAL PHARMACOLOGY****Pharmacodynamics**

Clomipramine (CMI) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought to be important.

## **ATTACHMENT 2**

Citizen Petition  
Ursodiol for Oral Administration

Labeling for reference product:  
Actigall® Ursodiol Oral Capsule, 300 mg (NDA 19-594)

9. Keep the patch dry, if possible, to prevent it from falling off. Limited contact with water, however, as in bathing or swimming, will not affect the system. In the unlikely event that the patch falls off, throw it away and put a new one behind the other ear.

This leaflet presents a summary of information about Transderm Scop. If you would like more information or if you have any questions, ask your doctor or pharmacist. A more technical leaflet is available, written for your doctor. If you would like to read the leaflet, ask your pharmacist to show you a copy. You may need the help of your doctor or pharmacist to understand some of the information.

Distributed by:

Novartis Consumer Health, Inc.  
Summit, N.J. 07901-1312

Shown in Product Identification Guide, page 324

## Novartis Pharmaceuticals Corporation

NOVARTIS PHARMACEUTICALS CORPORATION  
59 Route 10  
East Hanover, NJ 07936  
(for branded products)

GENEVA PHARMACEUTICALS, INC.  
A NOVARTIS COMPANY  
2655 West Midway Boulevard  
PO Box 446  
Broomfield, CO 80038-0446  
(for branded generic product listing refer to Geneva Pharmaceuticals, Inc.)

### For Information Contact (branded products):

Customer Response Department  
(888) NOW-NOVARTIS (888-669-6682)

Global Internet Address:  
<http://www.novartis.com>

### For Information Contact (branded generic products):

Customer Support Department  
(800) 525-8747  
(303) 466-2400  
FAX: (303) 469-6467

## ACTIGALL® [äct-i-gäll] ursodiol USP Capsules

**Caution:** Federal law prohibits dispensing without prescription.

The following prescribing information is based on official labeling in effect on August 1, 1998.


### SPECIAL NOTE

Gallbladder stone dissolution with Actigall treatment requires months of therapy. Complete dissolution does not occur in all patients and recurrence of stones within 5 years has been observed in up to 50% of patients who do dissolve their stones on bile acid therapy. Patients should be carefully selected for therapy with ursodiol, and alternative therapies should be considered.

### DESCRIPTION

Actigall is a bile acid available as 300-mg capsules suitable for oral administration.

Actigall is ursodiol USP (ursodeoxycholic acid), a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the bile of certain species of bears. It is a bitter-tasting, white powder freely soluble in ethanol, methanol, and glacial acetic acid; sparingly soluble in chloroform; slightly soluble in ether; and insoluble in water. The chemical name for ursodiol is 3 $\alpha$ , 7 $\beta$ -dihydroxy-5 $\beta$ -cholan-24-oic acid (C<sub>24</sub>H<sub>40</sub>O<sub>5</sub>). Ursodiol USP has a molecular weight of 392.58. Its structure is shown below:



**Inactive Ingredients.** Colloidal silicon dioxide, ferric oxide, gelatin, magnesium stearate, starch (corn), and titanium dioxide.

### CLINICAL PHARMACOLOGY

About 90% of a therapeutic dose of Actigall is absorbed in the small bowel after oral administration. After absorption, ursodiol enters the portal vein and undergoes efficient extraction from portal blood by the liver (i.e., there is a large "first-pass" effect) where it is conjugated with either glycine or taurine and is then secreted into the hepatic bile ducts. Ursodiol in bile is concentrated in the gallbladder and expelled into the duodenum in gallbladder bile via the cystic and common ducts by gallbladder contractions provoked by physiologic responses to eating. Only small quantities of ursodiol appear in the systemic circulation and very small amounts are excreted into urine. The sites of the drug's therapeutic actions are in the liver, bile, and gut lumen.

Beyond conjugation, ursodiol is not altered or catabolized appreciably by the liver or intestinal mucosa. A small proportion of orally administered drug undergoes bacterial degradation with each cycle of enterohepatic circulation. Ursodiol can be both oxidized and reduced at the 7-carbon, yielding either 7-keto-lithocholic acid or lithocholic acid, respectively. Further, there is some bacterially catalyzed deconjugation of glyco- and tauro- ursodeoxycholic acid in the small bowel. Free ursodiol, 7-keto-lithocholic acid, and lithocholic acid are relatively insoluble in aqueous media and larger proportions of these compounds are lost from the distal gut into the feces. Reabsorbed free ursodiol is re-conjugated by the liver. Eighty percent of lithocholic acid formed in the small bowel is excreted in the feces, but the 20% that is absorbed is sulfated at the 3-hydroxyl group in the liver to relatively insoluble lithocholyl conjugates which are excreted into bile and lost in feces. Absorbed 7-keto-lithocholic acid is stereospecifically reduced in the liver to chenodiol.

Lithocholic acid causes cholestatic liver injury and can cause death from liver failure in certain species unable to form sulfate conjugates. Lithocholic acid is formed by 7-dehydroxylation of the dihydroxy bile acids (ursodiol and chenodiol) in the gut lumen. The 7-dehydroxylation reaction appears to be alpha-specific, i.e., chenodiol is more efficiently 7-dehydroxylated than ursodiol and, for equimolar doses of ursodiol and chenodiol, levels of lithocholic acid appearing in bile are lower with the former. Man has the capacity to sulfate lithocholic acid. Although liver injury has not been associated with ursodiol therapy, a reduced capacity to sulfate may exist in some individuals, but such a deficiency has not yet been clearly demonstrated.

### Pharmacodynamics

Ursodiol suppresses hepatic synthesis and secretion of cholesterol, and also inhibits intestinal absorption of cholesterol. It appears to have little inhibitory effect on synthesis and secretion into bile of endogenous bile acids, and does not appear to affect secretion of phospholipids into bile.

With repeated dosing, bile ursodeoxycholic acid concentrations reach a steady state in about 3 weeks. Although insoluble in aqueous media, cholesterol can be solubilized in at least two different ways in the presence of dihydroxy bile acids. In addition to solubilizing cholesterol in micelles, ursodiol acts by an apparently unique mechanism to cause dispersion of cholesterol as liquid crystals in aqueous media. Thus, even though administration of high doses (e.g., 15-18 mg/kg/day) does not result in a concentration of ursodiol higher than 60% of the total bile acid pool, ursodiol-rich bile effectively solubilizes cholesterol. The overall effect of ursodiol is to increase the concentration level at which saturation of cholesterol occurs.

The various actions of ursodiol combine to change the bile of patients with gallstones from cholesterol-precipitating to cholesterol-solubilizing, thus resulting in bile conducive to cholesterol stone dissolution.

After ursodiol dosing is stopped, the concentration of the bile acid in bile falls exponentially, declining to about 5%-10% of its steady-state level in about 1 week.

### Clinical Results

#### Gallstone Dissolution

On the basis of clinical trial results in a total of 868 patients with radiolucent gallstones treated in 8 studies (three in the U.S. involving 282 patients, one in the U.K. involving 130 patients, and four in Italy involving 456 patients) for periods ranging from 6-78 months with Actigall doses ranging from about 5 to 20 mg/kg/day, an Actigall dose of about 8-10 mg/kg/day appeared to be the best dose. With an Actigall dose of about 10 mg/kg/day, complete stone dissolution can be anticipated in about 30% of unselected patients with uncalcified gallstones <20 mm in maximal diameter treated for up to 2 years. Patients with calcified gallstones prior to treatment, or patients who develop stone calcification or gallbladder nonvisualization on treatment, and patients with stones >20 mm in maximal diameter rarely dissolve their stones. The chance of gallstone dissolution is increased up to 50% in patients with floating or floatable stones (i.e., those with high cholesterol content), and is

inversely related to stone size for those <20 mm in maximal diameter. Complete dissolution was observed in 31% of patients with stones up to 5 mm in diameter. Age, sex, weight, degree of obesity, and serum cholesterol level are not related to the chance of stone dissolution with Actigall. A nonvisualizing gallbladder by oral cholecystogram prior to the initiation of therapy is not a contraindication to Actigall therapy (the group of patients with nonvisualizing gallbladders in the Actigall studies had complete stone dissolution rates similar to the group of patients with visualizing gallbladders). However, gallbladder nonvisualization developing during ursodiol treatment predicts failure of complete stone dissolution and in such cases therapy should be discontinued.

Partial stone dissolution occurring within 6 months of beginning therapy with Actigall appears to be associated with a >70% chance of eventual complete stone dissolution with further treatment; partial dissolution observed within 1 year of starting therapy indicates a 40% probability of complete dissolution.

Stone recurrence after dissolution with Actigall therapy was seen within 2 years in 8/27 (30%) of patients in the U.K. studies. Of 16 patients in the U.K. study whose stones had previously dissolved on chenodiol but later recurred, 11 had complete dissolution on Actigall. Stone recurrence has been observed in up to 50% of patients within 5 years of complete stone dissolution on ursodiol therapy. Serial ultrasonographic examinations should be obtained to monitor for recurrence of stones, bearing in mind that radiolucency of the stones should be established before another course of Actigall is instituted. A prophylactic dose of Actigall has not been established.

### Gallstone Prevention

Two placebo-controlled, multicenter, double-blind, randomized, parallel group trials in a total of 1316 obese patients were undertaken to evaluate Actigall in the prevention of gallstone formation in obese patients undergoing rapid weight loss. The first trial consisted of 1004 obese patients with a body mass index (BMI)  $\geq 38$  who underwent weight loss induced by means of a very low calorie diet for a period of 16 weeks. An intent-to-treat analysis of this trial showed that gallstone formation occurred in 23% of the placebo group, while those patients on 300, 600, or 1200 mg/day of Actigall experienced a 6%, 3%, and 2% incidence of gallstone formation, respectively. The mean weight loss for this 16-week trial was 47 lb for the placebo group, and 47, 48, and 60 lb for the 300, 600, and 1200 mg/day Actigall groups, respectively.

The second trial consisted of 312 obese patients (BMI  $\geq 40$ ) who underwent rapid weight loss through gastric bypass surgery. The trial drug treatment period was for 6 months following this surgery. Results of this trial showed that gallstone formation occurred in 23% of the placebo group, while those patients on 300, 600, or 1200 mg/day of Actigall experienced a 9%, 1%, and 5% incidence of gallstone formation, respectively. The mean weight loss for this 6-month trial was 64 lb for the placebo group, and 67, 74, and 72 lb for the 300, 600, and 1200 mg/day Actigall groups, respectively.

### ALTERNATIVE THERAPIES

#### Watchful Waiting

Watchful waiting has the advantage that no therapy may ever be required. For patients with silent or minimally symptomatic stones, the rate of development of moderate-to-severe symptoms or gallstone complications is estimated to be between 2% and 6% per year, leading to a cumulative rate of 7% to 27% in 5 years. Presumably the rate is higher for patients already having symptoms.

#### Cholecystectomy

For patients with symptomatic gallstones, surgery offers the advantage of immediate and permanent stone removal, but carries a high risk in some patients. About 5% of cholecystectomized patients have residual symptoms or retained common duct stones. The spectrum of surgical risk varies as a function of age and the presence of disease other than cholelithiasis.

**Mortality Rates for Cholecystectomy in the U.S.**  
(National Halothane Study, JAMA 1966; 197:775-8)  
27,600 Cholecystectomies (Smoothed Rates)  
Deaths/1000 Operations<sup>\*\*\*</sup>

| Low Risk Patients*   | Age (Yrs) | Cholecystectomy + Common Duct Exploration |       |
|----------------------|-----------|---|-------|
|                      |           | Cholecystectomy                           |       |
| Women                | 0-49      | .54                                       | 2.13  |
|                      | 50-69     | 2.80                                      | 10.10 |
| Men                  | 0-49      | 1.04                                      | 4.12  |
|                      | 50-69     | 5.41                                      | 19.23 |
| High Risk Patients** |           |   |       |
| Women                | 0-49      | 12.66                                     | 47.62 |
|                      | 50-69     | 17.24                                     | 58.82 |

Continued on next page

**Actigall—Cont.**

|     |       |       |        |
|-----|-------|-------|--------|
| Men | 0-49  | 24.39 | 90.91  |
|     | 50-69 | 33.33 | 111.11 |

\* In good health or with moderate systemic disease.

\*\* With severe or extreme systemic disease.

\*\*\* Includes both elective and emergency surgery.

Women in good health or who have only moderate systemic disease and are under 49 years of age have the lowest surgical mortality rate (0.054); men in all categories have a surgical mortality rate twice that of women. Common duct exploration quadruples the rates in all categories. The rates rise with each decade of life and increase tenfold or more in all categories with severe or extreme systemic disease.

**INDICATIONS AND USAGE**

- Actigall is indicated for patients with radiolucent, noncalcified gallbladder stones <20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of Actigall beyond 24 months is not established.
- Actigall is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

**CONTRAINDICATIONS**

- Actigall will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. Hence, patients with such stones are not candidates for Actigall therapy.
- Patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for Actigall therapy.
- Allergy to bile acids.

**PRECAUTIONS****Liver Tests**

Ursodiol therapy has not been associated with liver damage. Lithocholic acid, a naturally occurring bile acid, is known to be a liver-toxic metabolite. This bile acid is formed in the gut from ursodiol less efficiently and in smaller amounts than that seen from chenodiol. Lithocholic acid is detoxified in the liver by sulfation and, although man appears to be an efficient sulfator, it is possible that some patients may have a congenital or acquired deficiency in sulfation, thereby predisposing them to lithocholate-induced liver damage.

Abnormalities in liver enzymes have not been associated with Actigall therapy and, in fact, Actigall has been shown to decrease liver enzyme levels in liver disease. However, patients given Actigall should have SGOT (AST) and SGPT (ALT) measured at the initiation of therapy and thereafter as indicated by the particular clinical circumstances.

**Drug Interactions**

Bile acid sequestering agents such as cholestyramine and colestipol may interfere with the action of Actigall by reducing its absorption. Aluminum-based antacids have been shown to adsorb bile acids in vitro and may be expected to interfere with Actigall in the same manner as the bile acid sequestering agents. Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion, and encourage cholesterol gallstone formation and hence may counteract the effectiveness of Actigall.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Ursodeoxycholic acid was tested in 2-year oral carcinogenicity studies in CD-1 mice and Sprague-Dawley rats at daily doses of 50, 250, and 1000 mg/kg/day. It was not tumorigenic in mice. In the rat study, it produced statistically significant dose-related increased incidences of pheochromocytomas of adrenal medulla in males ( $p=0.014$ , Peto trend test) and females ( $p=0.004$ , Peto trend test). A 78-week rat study employing intrarectal instillation of lithocholic acid and tauro-deoxycholic acid, metabolites of ursodiol and chenodiol, has been conducted. These bile acids alone did not produce any tumors. A tumor-promoting effect of both metabolites was observed when they were co-administered with a carcinogenic agent. Results of epidemiologic studies suggest that bile acids might be involved in the pathogenesis of human colon cancer in patients who had undergone a cholecystectomy, but direct evidence is lacking. Ursodiol is not mutagenic in the Ames test. Dietary administration of lithocholic acid to chickens is reported to cause hepatic adenomatous hyperplasia.

**Pregnancy Category B**

Reproduction studies have been performed in rats and rabbits with ursodiol doses up to 200-fold the therapeutic dose and have revealed no evidence of impaired fertility or harm to the fetus at doses of 20- to 100-fold the human dose in rats and at 5-fold the human dose (highest dose tested) in

rabbits. Studies employing 100- to 200-fold the human dose in rats have shown some reduction in fertility rate and litter size. There have been no adequate and well-controlled studies of the use of ursodiol in pregnant women, but inadvertent exposure of 4 women to therapeutic doses of the drug in the first trimester of pregnancy during the Actigall trials led to no evidence of effects on the fetus or newborn baby. Although it seems unlikely, the possibility that ursodiol can cause fetal harm cannot be ruled out; hence, the drug is not recommended for use during pregnancy.

**Nursing Mothers**

It is not known whether ursodiol is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Actigall is administered to a nursing mother.

**Pediatric Use**

The safety and effectiveness of Actigall in pediatric patients have not been established.

**ADVERSE REACTIONS**

The nature and frequency of adverse experiences were similar across all groups.

The following tables provide comprehensive listings of the adverse experiences reported that occurred with a 5% incidence level:

**GALLSTONE DISSOLUTION**

|  | Ursodiol<br>8-10 mg/kg/day<br>(N=155) |        | Placebo<br>(N=159) |        |
|--|---------------------------------------|--------|--------------------|--------|
|  | N                                     | (%)    | N                  | (%)    |
| <b>Body as a Whole</b>                   |                                       |        |                    |        |
| Allergy                                  | 8                                     | (5.2)  | 7                  | (4.4)  |
| Chest Pain                               | 5                                     | (3.2)  | 10                 | (6.3)  |
| Fatigue                                  | 7                                     | (4.5)  | 8                  | (5.0)  |
| Infection Viral                          | 30                                    | (19.4) | 41                 | (25.8) |
| <b>Digestive System</b>                  |                                       |        |                    |        |
| Abdominal Pain                           | 67                                    | (43.2) | 70                 | (44.0) |
| Cholecystitis                            | 8                                     | (5.2)  | 7                  | (4.4)  |
| Constipation                             | 15                                    | (9.7)  | 14                 | (8.8)  |
| Diarrhea                                 | 42                                    | (27.1) | 34                 | (21.4) |
| Dyspepsia                                | 26                                    | (16.8) | 18                 | (11.3) |
| Flatulence                               | 12                                    | (7.7)  | 12                 | (7.5)  |
| <b>Gastrointestinal</b>                  |                                       |        |                    |        |
| Disorder                                 | 6                                     | (3.9)  | 8                  | (5.0)  |
| Nausea                                   | 22                                    | (14.2) | 27                 | (17.0) |
| Vomiting                                 | 15                                    | (9.7)  | 11                 | (6.9)  |
| <b>Musculoskeletal System</b>            |                                       |        |                    |        |
| Arthralgia                               | 12                                    | (7.7)  | 24                 | (15.1) |
| Arthritis                                | 9                                     | (5.8)  | 4                  | (2.5)  |
| Back Pain                                | 11                                    | (7.1)  | 18                 | (11.3) |
| Myalgia                                  | 9                                     | (5.8)  | 9                  | (5.7)  |
| <b>Nervous System</b>                    |                                       |        |                    |        |
| Headache                                 | 28                                    | (18.1) | 34                 | (21.4) |
| Insomnia                                 | 3                                     | (1.9)  | 8                  | (5.0)  |
| <b>Respiratory System</b>                |                                       |        |                    |        |
| Bronchitis                               | 10                                    | (6.5)  | 6                  | (3.8)  |
| Coughing                                 | 11                                    | (7.1)  | 7                  | (4.4)  |
| Pharyngitis                              | 13                                    | (8.4)  | 5                  | (3.1)  |
| Rhinitis                                 | 8                                     | (5.2)  | 11                 | (6.9)  |
| Sinusitis                                | 17                                    | (11.0) | 18                 | (11.3) |
| <b>Upper Respiratory Tract Infection</b> |                                       |        |                    |        |
|  | 24                                    | (15.5) | 21                 | (13.2) |
| <b>Urogenital System</b>                 |                                       |        |                    |        |
| <b>Urinary Tract Infection</b>           |                                       |        |                    |        |
|  | 10                                    | (6.5)  | 7                  | (4.4)  |

**GALLSTONE PREVENTION**

|                               | Actigall<br>600 mg<br>(N=322) |        | Placebo<br>(N=325) |        |
|-------------------------------|-------------------------------|--------|--------------------|--------|
|                               | N                             | (%)    | N                  | (%)    |
| <b>Body as a Whole</b>        |                               |        |                    |        |
| Fatigue                       | 25                            | (7.8)  | 33                 | (10.2) |
| Infection Viral               | 29                            | (9.0)  | 29                 | (8.9)  |
| Influenza-like Symptoms       | 21                            | (6.5)  | 19                 | (5.8)  |
| <b>Digestive System</b>       |                               |        |                    |        |
| Abdominal Pain                | 20                            | (6.2)  | 39                 | (12.0) |
| Constipation                  | 85                            | (26.4) | 72                 | (22.2) |
| Diarrhea                      | 81                            | (25.2) | 68                 | (20.9) |
| Flatulence                    | 15                            | (4.7)  | 24                 | (7.4)  |
| Nausea                        | 56                            | (17.4) | 43                 | (13.2) |
| Vomiting                      | 44                            | (13.7) | 44                 | (13.5) |
| <b>Musculoskeletal System</b> |                               |        |                    |        |
| Back Pain                     | 38                            | (11.8) | 21                 | (6.5)  |
| Musculoskeletal Pain          | 19                            | (5.9)  | 15                 | (4.6)  |
| <b>Nervous System</b>         |                               |        |                    |        |
| Dizziness                     | 53                            | (16.5) | 42                 | (12.9) |
| Headache                      | 80                            | (24.8) | 78                 | (24.0) |

|  |    |        |    |        |
|--|----|--------|----|--------|
| <b>Respiratory System</b>                |    |        |    |        |
| Pharyngitis                              | 10 | (3.1)  | 19 | (5.8)  |
| Sinusitis                                | 17 | (5.3)  | 18 | (5.5)  |
| <b>Upper Respiratory Tract Infection</b> |    |        |    |        |
|  | 40 | (12.4) | 35 | (10.8) |
| <b>Skin and Appendages</b>               |    |        |    |        |
| Alopecia                                 | 17 | (5.3)  | 8  | (2.5)  |
| <b>Urogenital System</b>                 |    |        |    |        |
| Dysmenorrhea                             | 18 | (5.6)  | 19 | (5.8)  |

**OVERDOSAGE**

Neither accidental nor intentional overdosing with Actigall has been reported. Doses of Actigall in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD<sub>50</sub> for ursodiol in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdose with Actigall would probably be diarrhea, which should be treated symptomatically.

**DOSAGE AND ADMINISTRATION****Gallstone Dissolution**

The recommended dose for Actigall treatment of radiolucent gallbladder stones is 8-10 mg/kg/day given in 2 or 3 divided doses.

Ultrasound images of the gallbladder should be obtained at 6-month intervals for the first year of Actigall therapy to monitor gallstone response. If gallstones appear to have dissolved, Actigall therapy should be continued and dissolution confirmed on a repeat ultrasound examination within 1 to 3 months. Most patients who eventually achieve complete stone dissolution will show partial or complete dissolution at the first on-treatment reevaluation. If partial stone dissolution is not seen by 12 months of Actigall therapy, the likelihood of success is greatly reduced.

**Gallstone Prevention**

The recommended dosage of Actigall for gallstone prevention in patients undergoing rapid weight loss is 600 mg/day (300 mg b.i.d.).

**HOW SUPPLIED**

Capsules 300 mg — opaque, white, pink (imprinted Actigall 300 mg)

Bottles of 100 ..... NDC 0078-0319-05

Do not store above 86°F (30°C).

Dispense in tight container (USP).

C97-12 (Rev. 12/97)

**Distributed by**

Novartis Pharmaceuticals Corporation

East Hanover, New Jersey 07936

Shown in Product Identification Guide, page 324

**ANAFRANIL®**

[a<sub>1</sub> frānil]

clomipramine hydrochloride

Capsules


Caution: Federal law prohibits dispensing without prescription.

The following prescribing information is based on official labeling in effect on August 1, 1998.

**DESCRIPTION**

Anafranil, clomipramine hydrochloride, is an antiobsessive drug that belongs to the class (dibenzazepine) of pharmacologic agents known as tricyclic antidepressants. Anafranil is available as capsules of 25, 50, and 75 mg for oral administration.

Clomipramine hydrochloride is 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine mono hydrochloride and its structural formula is



Clomipramine hydrochloride is a white to off-white crystal line powder. It is freely soluble in water, in methanol, and in methylene chloride, and insoluble in ethyl ether and in hexane. Its molecular weight is 351.3.

**Inactive Ingredients.** D&C Red No. 33 (25-mg capsule only), D&C Yellow No. 10, FD&C Blue No. 1 (50-mg capsules only), FD&C Yellow No. 6, gelatin, magnesium stearate, methylparaben, propylparaben, silicon dioxide, sodium lauryl sulfate, starch, and titanium dioxide.

**CLINICAL PHARMACOLOGY****Pharmacodynamics**

Clomipramine (CMI) is presumed to influence obsessive compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought to be important.

FROM  
 TO  
 Gordon Johnson 116-00-101  
 Food & Drug Administration  
 5630 Fishers Lane Room 1061  
 Rockville MD 20852  
 Doc. H.T. M... ..

Payment  
 Origin Airbill Number 2957198532

Bill to:  
 Receiver ☐ 3rd Party ☐  
☐ Paid in Advance

Billing Reference (will appear on invoice)

# of Pkgs 1 Weight (LBS) Packaging Letter Express ☒ Express Pack ☐ Other Packaging ☐ One box must be checked

Special Instructions  
☐ SAT ☐ HAA  
☐ LAB ☐

EXP (Letter - 150 lbs)  
 NAS (Letter - 5 lbs)  
 SDS (Letter - 150 lbs)

295 719 8532



MLDA/YK ABA

NOTICE: Airborne Express cannot deliver without your airbill attached here.

### United States Shipping

Complete applicable white sections of the U.S. Airbill. Sign and date the Airbill at the Sender's Signature line. Please press hard. Peel off protective covering from back of Airbill. Fix Airbill to envelope within dotted lines shown. When using a Drop Box - follow special instructions on the Drop Box.

### International Shipping

Includes Canada & Puerto Rico

Must be typed

Complete applicable white sections of the International Express Airbill. Sign and date the Airbill at the Sender's Signature line. Place Airbill in plastic sleeve. Peel off bottom portion from back of plastic sleeve. Do not seal top portion of the plastic sleeve to the envelope. Fix bottom portion to envelope within the dotted lines shown. Airborne driver must sign Airbill before sealing.

### Limitation on Contents

The maximum acceptable contents of a Letter Express is forty (40) 8-1/2 x 11 pages. If the gross weight of the contents, envelope and airbill exceeds 1/2 pound, the next higher rate will apply. Contents must be of a size and shape which fit the envelope and allow it to be securely sealed without damage. Cash or cash equivalent should not be shipped. Items of high intrinsic value should not be shipped in Letter Express packaging.

### Limitations of Liability

Liability of Airborne Express is limited on Letter Express to \$100.00 U.S.D., unless a higher value is declared for carriage on our airbill. The maximum declared value on the Letter Express is \$500.00 U.S.D. Airborne Express shall not be liable in any event for special, incidental or consequential damages, including but not limited to loss of profits or income. Services are provided as defined in the current Airborne Express Service Guide (subject to change without notice). Copies are available upon request.

To reach your local CUSTOMER SERVICE CENTER Call 1-800-AIRBORNE (1-800-247-2676) U.S. only.